Overall, the results of this study demonstrated that PTPRD/PTPRT mutations are correlated with a poor prognosis and that PTPRD/PTPRT mutations might act as a pan-cancer biomarker for the prediction of ICI treatment efficacy. The gene discussed is PTPRD; the disease is cancer.